NasdaqGS - Nasdaq Real Time Price USD

Genfit S.A. (GNFT)

3.4500

+0.0050

(+0.15%)

At close: April 25 at 4:00 PM EDT

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, today announced the publication of its 2024 Extra-Financial Performance Report (fiscal year 2023). Third edition of the Extra-Financial Performance report Since 2022, GENFIT has published a detailed Extra-Financial Performance report in response to

GlobeNewswire 13 hours ago

GNFT
+0.15%
GNFTF
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the April 15, 2024 French legal announcements bulletin n°46 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 22, 2024, at 1

GlobeNewswire 10 days ago

GNFT
+0.15%
GNFTF
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 5, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the filing of its 2023 Universal Registration Document with the Autorité des marchés financiers (AMF ; filing n° D.24-0246) and its Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities

GlobeNewswire 20 days ago

GNFT
+0.15%
GNFTF
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 millionTopline interim data for Phase 2 UNVEIL-IT® trial in ACLF expected in 2H24FDA PDUFA action date for elafibranor in PBC: June 10, 2024 Lille, France; Cambridge, MA; Zurich, Switzerland; April 4, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients wit

GlobeNewswire 21 days ago

GNFT
+0.15%
GNFTF
GENFIT Announces Revenues and Cash Position as of December 31, 2023

Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 million Upcoming FDA PDUFA action date for elafibranor in PBC: June 10, 2024 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liv

GlobeNewswire last month

GNFT
+0.15%
GNFTF
GENFIT Announces 2024 Financial Calendar

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2024. 2024 Financial Calendar February 29, 2024 Publication of revenue and cash position at December 31, 2023 April 4, 2024 Publication of Full Year 2023 financial statements The

GlobeNewswire 3 months ago

GNFT
+0.15%
GNFTF
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 11, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity accoun

GlobeNewswire 3 months ago

GNFT
+0.15%
GNFTF
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

US Food and Drug Administration (FDA) has granted Priority Review for New Drug Application (NDA) for elafibranor in PBC, and European Medicine Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor.Acceptance triggers a first milestone payment. Further milestones are expected upon US and European launches which could now happen in 2Q24 in the US (FDA PDUFA1 action date: June 10, 2024) and 2H24 in Europe. These milestones total approximately 89M€. Launches i

GlobeNewswire 4 months ago

GNFT
+0.15%
GNFTF
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

New Drug Application granted priority review with PDUFA date set for June 10, 2024European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor Investigational elafibranor is the first novel second-line treatment for primary biliary cholangitis (PBC) to be filed in E.U. and U.S. in nearly a decade Paris (France), December 07, 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Dr

GlobeNewswire 4 months ago

GNFT
+0.15%
GNFTF
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

The paper published in Journal of Hepatology demonstrates that NIS2+™ technology could significantly reduce liver biopsy failure rate and maximizes accuracy of patient selection for MASH1 clinical trialsGrowing body of clinical evidence: this is the third paper on NIS2+™ that has been published in a leading medical journal in 2023 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 6, 2023- GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical co

GlobeNewswire 4 months ago

GNFT
+0.15%
GNFTF
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

GENFIT highlighted new focus and development strategy in Acute On-Chronic Liver Failure (ACLF)ACLF is a very serious condition affecting ~294,0001 2 patients with chronic liver diseases in the USA and Europe every year and is associated with multi-organ failure and high short-term mortalityIt is an underserved medical condition with currently no approved treatment and few programs under development globallyGENFIT has developed a unique pipeline of 5 different drug candidates targeting key pathop

GlobeNewswire 5 months ago

GNFT
+0.15%
GNFTF
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

ELATIVE® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR α,δ agonist for patients with Primary Biliary Cholangitis.Elafibranor demonstrates significant improvements in biomarkers of disease progression versus placebo, including significant treatment benefit with improvement in biochemical response and alkaline phosphatase (ALP) normalization, along with patient-reported outcomes data suggesting a possible improvement in pruritus.Elafibrano

GlobeNewswire 5 months ago

GNFT
+0.15%
GNFTF
GENFIT Reports Third Quarter 2023 Financial Information

Cash and cash equivalents totaled €93.9 million as of September 30, 2023 Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); November 9, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of September 30, 2023 and revenue for the first nine months of 20231. Cash Position As of September 30, 2023, the Company’s

GlobeNewswire 5 months ago

GNFT
+0.15%
GNFTF
GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

GENFIT to lead 3 key events on ACLF during AASLD: ACLF Day for Investors/Analysts on November 11, 2023Patient Advocacy Council meeting on November 11, 2023ACLF Investigator event on November 12, 2023 Detailed interim data from the ELATIVE® Phase 3 results evaluating elafibranor in PBC to be presented by GENFIT’s partner Ipsen, in a late breaking oral session on November 13, 2023GENFIT to present new data on its NASH1 diagnostics technology Lille (France), Cambridge (Massachusetts, United States)

GlobeNewswire 5 months ago

GNFT
+0.15%
GNFTF
GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); September 26, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of data demonstrating the effectiveness of its non-alcoholic steatohepatitis (NASH)1 diagnostic technology NIS4® by the FNIH’s2 NIMBLE3 project in the scientific journal, Nature Medicine4. NIMBLE, part of the F

GlobeNewswire 6 months ago

GNFT
+0.15%
GNFTF
GENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for GENFIT S.A. Unsponsored ADR (GNFT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks 6 months ago

GNFT.PA
GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update

Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE® trial in June 2023, paving the way to: a potential submission to the health authorities by Ipsen, and a potential first milestone met before the end of 2023, and if approved, commercialization would trigger further milestone payments and royalty payments GENFIT’s leadership in ACLF is further strengthened, with now 5 complementary assets in development,

GlobeNewswire 7 months ago

GNFT
+0.15%
GNFTF
GENFIT to Participate in Upcoming Investor Conferences

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 05, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will participate in the following upcoming investor conferences. Morgan Stanley 21st Annual Global Healthcare Conference Date: September 11-13, 2023Location: New York H.C. Wainwright 25th Annual Global Investment Confe

GlobeNewswire 7 months ago

GNFT
+0.15%
GNFTF
GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); August 10, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of new data on the clinical performance of NIS2+™ in older patients, for the detection of at-risk nonalcoholic steatohepatitis (NASH) in Hepatology Communications1. In conjunction with Labcorp, a global leader of

GlobeNewswire 8 months ago

GNFT
+0.15%
GNFTF
Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients

Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT) announced topline data from the Phase 3 ELATIVE trial evaluating the efficacy and safety of elafibranor for primary biliary cholangitis (PBC) who have shown inadequate response or intolerance to ursodeoxycholic acid (UDCA), the current standard therapy. PBC is a chronic disease in which the bile ducts in the liver are slowly destroyed. The trial met its primary composite endpoint, with 51% of patients on elafibranor 80mg exhibiting a cholestasis

Benzinga 9 months ago

IPSEY

GNFT.PA

Performance Overview

Return	GNFT	CAC 40
YTD	-10.39%	+6.54%
1-Year	-7.75%	+6.70%
3-Year	-18.63%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Genfit S.A. (GNFT)

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

GENFIT Announces Revenues and Cash Position as of December 31, 2023

GENFIT Announces 2024 Financial Calendar

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

GENFIT Reports Third Quarter 2023 Financial Information

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology

GENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update

GENFIT to Participate in Upcoming Investor Conferences

GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications

Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients

Performance Overview